Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: rheumatoid arthritis US FDA label
Kidney dosing: Naproxen (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Usual: naproxen 250 to 500 mg twice daily, or naproxen sodium 275 to 550 mg twice daily; lowest effective dose, shortest duration (label).
- CrCl 30–59 mL/min
- No label dose change at CrCl ≥30. Monitor creatinine, potassium and blood pressure; avoid volume depletion and the ACE inhibitor or ARB plus diuretic combination (label 5.6). Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
- CrCl 15–29 mL/min
- Not recommended at CrCl <30 mL/min (moderate to severe and severe impairment; label 8.7). Naproxen metabolites accumulate in kidney failure. Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
- CrCl <15 mL/min (not on dialysis)
- Not recommended at CrCl <30 mL/min (moderate to severe and severe impairment; label 8.7). Naproxen metabolites accumulate in kidney failure. Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
- Hemodialysis (intermittent)
- Not recommended (CrCl <30; label). NSAIDs may hasten loss of residual kidney function.
- Peritoneal dialysis
- Not recommended (CrCl <30; label). NSAIDs may hasten loss of residual kidney function.
- CRRT
- Avoid: NSAIDs can worsen acute kidney injury.
- Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (over 99%; label 10).
- Monitoring Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Naproxen sodium contains sodium (about 2 mEq per 500 mg naproxen).
From the Naproxen monograph (renalcarematters.com, reviewed).
Use: Treatment of active duodenal ulcer in adults US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Capsule: 275 mg/10 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Naproxen + Omeprazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
NaprotectNaproxen Sodium + Omeprazole | 275mg/ 10mg CapsuleAluminum Flex Foil Strip x 6's (Box of 60's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-11165 | Feb 15, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .